Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1632 1647 4111
This examiner grants 24% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18361367 | ANTI-TFR:PAYLOAD FUSIONS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18352081 | METHODS AND COMPOSITIONS FOR PRODUCING TARGETED MICROBUBBLES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18448665 | PREPARATION METHOD OF CITRULLINATED VIMENTIN ANTIGEN-SPECIFIC IMMUNE TOLEROGENIC DENDRITIC CELLS, AND USES THEREOF | Non-Final OA | Daegu Gyeongbuk Institute of Science and Technology |
| 18448821 | METHODS FOR ACTIVATING IMMUNE CELLS AND TREATING OCULAR NEOVASCULARIZATION | Non-Final OA | WASHINGTON UNIVERSITY |
| 18360542 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | Non-Final OA | MedImmune, LLC |
| 18327402 | CLAUDIN 18.2 ANTIBODIES, METHODS OF MAKING THE SAME, AND USES THEREOF | Non-Final OA | Integral Molecular, Inc. |
| 17082955 | SEPARATION MOIETIES AND METHODS OF USE THEREOF | Non-Final OA | Werewolf Therapeutics, Inc. |
| 18303407 | DNA THERAPEUTIC ENCODING AN ANTIBODY OR ANTIGEN BINDING FRAGMENT | Non-Final OA | Entos Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy